Table 1 Population characteristics for patients with metastatic urothelial carcinoma treated by first-line cisplatin-based chemotherapy (n = 113)
Characteristics | n (%) |
|---|---|
Male/female | 91 (80.5) / 22 (19.5) |
Age in years, (median [range]) | 63.24 [33.7–79.7] |
Performance Status | |
0 | 46 (40.7) |
1 | 50 (44.2) |
2–3 | 17 (15.0) |
Metastatic relapse | |
Yes | 41 (36.3) |
No | 72 (63.7) |
Number of metastatic sites | |
1 | 39 (34.5) |
2 | 51 (45.1) |
3 | 17 (15) |
>3 | 6 (5.3) |
Metastatic sites (non-exclusive) | |
Lymph node under the diaphragm | 84 (74.3) |
Lymph node above the diaphragm | 20 (17.7) |
Bone | 36 (31.9) |
Lung | 44 (38.9) |
Liver | 23 (20.4) |
Other | 8 (7.1) |
Visceral metastases (lung – liver – bone) | 77 (68.1) |
Haemoglobin level | |
>11g/dl | 61 (54) |
<11g/dl | 42 (37.2) |
Unknown | 10 (8.8) |
Creatinine clearance | |
Normal | 76 (67.3) |
Abnormal | 20 (17.7) |
Unknown | 17 (15) |
AP | |
Normal | 48 (42.5) |
Abnormal | 32 (28.3) |
Unknown | 33 (29.2) |
LDH | |
Normal | 36 (31.9) |
Abnormal | 24 (21.2) |
Unknown | 53 (46.9) |
Chemotherapy | |
G-C | 86 (76.1) |
M-VAC | 12 (10.6) |
G-C switched to G-Carboplatin | 15 (13.3) |
Response following 2 or 3 cycles | |
CR | 3 (2.7) |
PR | 61 (54) |
SD | 38 (33.6) |
PD | 11 (9.7) |
EOR | 64 (56.7) |
Subsequent treatmentsa | 51 (45.1) |
Chemotherapy | 46 (40.7) |
Chemoradiotherapy | 5 (4.4) |
Radiotherapy | 0 |